Photo of the Discovery Park House building at night Ixchelsis Limited is an independent biotechnology company based in Discovery Park, Sandwich, UK. Ixchelsis has achieved positive proof of concept with IX-01, an investigational compound, originally discovered at Pfizer’s, Sandwich, UK, R&D site. IX-01 is an Oxytocin receptor antagonist with the potential to treat the male sexual health indication, premature ejaculation (PE).

Chemistry science formula and tablets. Medicine symbol.PE is a highly distressing medical condition with limited treatment options in the EU and currently no approved therapies in the US. Ixchelsis has a highly experienced management team with an excellent track record both in clinical development and the field of male sexual health. Ixchelsis raised a total of $26 million financing from TVM Life Science Ventures VII and Pfizer Ventures.